+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer



Short-term outcome of neoadjuvant gemcitabine-carboplatin therapy for muscle-invasive bladder cancer



Gan to Kagaku Ryoho. Cancer and ChemoTherapy 35(1): 83-86



Twenty-three patients with muscle-invasive bladder cancer were treated with combination chemotherapy of gemcitabine and carboplatin. Gemcitabine at a dose of 800 mg/m2 by intravenous infusion for 30 minutes on Days 1, 8 and 15. Carboplatin at an AUC of 4, according to the Calvert formula, was administered by intravenous infusion for 3 hours on Day 2. The treatment was repeated every 21 days without drug-free-weeks for a total of 2 cycles. Six patients achieved a complete response(CR)and 8 patients achieved a partial response(PR). Overall response rate(CR+PR) was 60.8%. In addition, 7 patients achieved stable disease(SD), whereas 2 were found to have progressive disease (PD). Although Grade 3 or 4 leukocytopenia was seen in 10 patients(43.4%), low-grade toxicities of anemia, thrombocytopenia and nausea were seen in several patients, so it was possible to complete the treatment on schedule in all patients. Five SD patients died(4 by cancer and 1 by another cause), 2 PD patients were found to have disease progression, and 16 patients were alive without recurrence with a mean follow-up period of 12.6 months(range: 8-19).

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 055761258

Download citation: RISBibTeXText

PMID: 18195533


Related references

Neoadjuvant chemotherapy with gemcitabine plus carboplatin followed by immediate radical cystectomy for muscle-invasive bladder cancer. International Journal of Urology 21(1): 3-4, 2014

Neoadjuvant Gemcitabine Plus Carboplatin Followed By Immediate Radical Cystectomy In Patients With Muscle-Invasive Bladder Cancer: A Propensity Score Analysis. The Journal of Urology 187(4): e217-e218, 2012

The utility of neoadjuvant gemcitabine plus carboplatin followed by immediate radical cystectomy in patients with muscle-invasive bladder cancer who are ineligible for cisplatin-based chemotherapy. International Journal of Clinical Oncology 22(1): 159-165, 2017

Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study. International Journal of Clinical Oncology 18(4): 724-730, 2013

Cisplatin, Gemcitabine, and Lapatinib as Neoadjuvant Therapy for Muscle-Invasive Bladder Cancer. Cancer Research and Treatment 48(3): 1084-1091, 2016

Tolerability of Concurrent Chemoradiation Therapy With Gemcitabine (GemX), With and Without Prior Neoadjuvant Chemotherapy, in Muscle Invasive Bladder Cancer. International Journal of Radiation Oncology Biology Physics 97(4): 732-739, 2017

Neoadjuvant gemcitabine plus cisplatin for muscle-invasive bladder cancer. Japanese Journal of Clinical Oncology 41(7): 908-914, 2011

Comparative effectiveness of gemcitabine plus cisplatin versus methotrexate, vinblastine, doxorubicin, plus cisplatin as neoadjuvant therapy for muscle-invasive bladder cancer. Cancer 121(15): 2586-2593, 2015

Intravesical Gemcitabine Versus Bacillus Calmette-Guerin ( Bcg) In Treatment Of Non-Muscle Invasive Bladder Cancer: Short Term Comparative Study. The Journal of Urology 185(4): e664-e665, 2011

Comparison between neoadjuvant and adjuvant gemcitabine plus cisplatin chemotherapy for muscle-invasive bladder cancer. Asia-Pacific Journal of Clinical Oncology 9(4): 310-317, 2013

Is neoadjuvant chemotherapy with gemcitabine plus cisplatin beneficial in patients with muscle-invasive bladder cancer?. Expert Review of Anticancer Therapy 9(6): 747-752, 2009

Improving the outcome of patients with muscle invasive urothelial carcinoma of the bladder with neoadjuvant gemcitabine/cisplatin chemotherapy: A single institution experience. Canadian Urological Association Journal 8(3-4): E287-E293, 2014

A sequential treatment approach to muscle-invasive urothelial cancer: A phase II Southwest Oncology Group Trial (S0219) of neoadjuvant paclitaxel, carboplatin, and gemcitabine (PCG). Journal of Clinical Oncology 26(15_Suppl): 5022-5022, 2016

Retrospective analysis of the efficacy and safety of neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer. Journal of Oncology Pharmacy Practice 2019: 1078155219845434, 2019

Neoadjuvant chemotherapy with gemcitabine and cisplatin for muscle-invasive bladder cancer: multicenter retrospective study. Japanese Journal of Clinical Oncology 48(10): 934-941, 2018